Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

How Nuformix plc (LSE:NFX) Evaluates Cocrystal Solid-State Stability to Enhance Drug Dissolution Rates

Nuformix plc (LSE:NFX) has continued to advance its focused pharmaceutical development strategy, leveraging cocrystal technology to repurpose and reformulate proven pharmaceutical molecules for severe unmet medical needs. The development-stage biopharmaceutical company utilizes crystal engineering to improve the physical properties, dissolution rates, and therapeutic bioavailability …

Ankur Sharma | 14 October 2026

Why Oxford BioDynamics Plc (LSE:OBD) Emphasises Blood-Based Chromosome Conformation Signatures for Non-Invasive Screening

Oxford BioDynamics Plc (LSE:OBD) has continued the commercial rollout of its proprietary EpiSwitch® 3D genomic biomarker platform across clinical diagnostic and oncology markets. The biotechnology company translates three-dimensional chromosome conformation changes into precision diagnostic blood tests. Unlike standard genomic sequencing that only detects fixed …

Ankur Sharma | 14 October 2026

Why Ondine Biomedical, Inc. (LSE:OBI) Prioritises Pre-Surgical Orthopaedic Decolonisation Protocols in Intensive Care Units

Ondine Biomedical, Inc. (LSE:OBI) has accelerated the international deployment of its proprietary photodisinfection technology to combat hospital-acquired infections and antimicrobial resistance. The Canadian-headquartered medical technology company utilizes light-activated antimicrobial agents to rapidly destroy bacteria, viruses, and fungi without generating drug resistance. Its flagship platform, …

Ankur Sharma | 14 October 2026

Why OptiBiotix Health PLC (LSE:OPTI) Targets Sports Nutrition Brands for Prebiotic Functional Fibre Blends

OptiBiotix Health PLC (LSE:OPTI) has accelerated the global commercialisation of its proprietary microbiome and functional food formulations across dietary supplement, pharmaceutical, and consumer healthcare industries. The life sciences company discovers and develops scientifically validated compounds that modulate the human microbiome. The group's primary intellectual …

Ankur Sharma | 14 October 2026

Why Oxford BioMedica plc (LSE:OXB) Focuses on High-Yield Suspension Cell Culture Bioreactors

Oxford BioMedica plc (LSE:OXB) has completed its strategic transformation from an internal drug developer into a pure-play contract development and manufacturing organisation (CDMO) specializing in viral vectors. The biotechnology leader designs and manufactures lentiviral, adeno-associated virus (AAV), and adenoviral vectors for global cell and …

Ankur Sharma | 14 October 2026

Why Probiotix Health plc (LSE:PBX) Targets Dairy and Fermented Beverage Manufacturers for Probiotic Integration

Probiotix Health Plc (LSE:PBX) has achieved a decisive operational and financial inflection point, transitioning into statutory EBITDA profitability while accelerating commercial partnership revenues across international healthcare markets. The life sciences company discovers and commercialises patented probiotic formulations. The company's lead commercial asset, Lactobacillus plantarum …

Ankur Sharma | 14 October 2026

How Poolbeg Pharma plc (LSE:POLB) Validates In Silico Target Identification Platforms for Metabolic Drug Screening

Poolbeg Pharma plc (LSE:POLB) has maintained active clinical development momentum across its diversified portfolio of therapeutic candidates targeting severe hyperinflammation, cancer immunotherapy complications, and infectious diseases. The clinical-stage biopharmaceutical company utilizes a capital-light, fast-track development model. By leveraging human challenge trial data and artificial …

Ankur Sharma | 14 October 2026

What hVIVO (LSE:HVO) Details Concerning Human Challenge Viral Models and Outpatient Clinical Trial Capacity

hVIVO plc (LSE:HVO) has solidified its global market leadership in human challenge clinical trials, completing the operational expansion and commercial ramp-up of its state-of-the-art quarantine trial facility in Canary Wharf, London. Quoted on the AIM market of the London Stock Exchange, the specialist contract …

Divya Sood | 14 October 2026

What Cambridge Nutritional Sciences PLC (LSE:CNSL) Outlined on Reagent Batch Consistency for IgG Antibody Profiling

Cambridge Nutritional Sciences PLC (LSE:CNSL) has accelerated its strategic repositioning to capture growing international demand for personalised health, nutrition, and food intolerance diagnostics. The company—formerly known as Omega Diagnostics Group PLC—has finalised its operational transition from a diversified point-of-care medical testing group into a …

Ankur Sharma | 14 October 2026

What Coiled Therapeutics PLC (LSE:COIL) Outlined for Preclinical Enzyme Inhibition Selectivity in Tissue Remodelling Assays

Coiled Therapeutics PLC (LSE:COIL) has advanced its focused biopharmaceutical development operations, concentrating scientific resources on early-stage target validation and preclinical candidate nomination across high-unmet-need therapeutic indications. The development-stage life sciences company investigates novel biological pathways and molecular targets implicated in chronic inflammatory, fibrotic, and …

Ankur Sharma | 14 October 2026
Support

Hi! How can we help you today?

Loading…